Navigation Links
Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 in Adults With Chronic Genotype 1 HCV
Date:2/18/2011

>About Tibotec Pharmaceuticals Tibotec Pharmaceuticals is a global pharmaceutical and research development company. The Company's main research and development facilities are in Beerse, Belgium with offices in Titusville, NJ and Cork, Ireland. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS and hepatitis C drugs, and anti-infectives for diseases of high unmet medical need. Tibotec Pharmaceuticals is a subsidiary of Johnson & Johnson.

Forward Looking StatementThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Tibotec and/or Johnson & Johnson's expectations and projections.  Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment.  A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2010.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  Neither Tibotec nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.Contacts: Media

Investor RelationsKa
'/>"/>

SOURCE Tibotec Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
2. Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
3. Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
4. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
5. Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds
6. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
7. Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS
8. Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers
9. Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
10. Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD
11. Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... BOULDER, Colo. , Jan. 22, 2015  BiOptix is ... Klakamp as Vice President of Chemistry and Biochemistry. Scott ... Takeda Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course ... and development. "Scott is a nationally recognized ...
(Date:1/22/2015)... , Jan. 22, 2015  Amgen (NASDAQ: AMGN ) today ... 2014 financial results on Tuesday, Jan. 27, 2015, after the close ... a conference call with the investment community at 2 p.m. PT. ... Bradway , chairman and chief executive officer, and other members of ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... In Follow-up Period -, EXTON, Pa., Jan. ... injections have been completed in the pivotal,Phase III ... Therapy(TM) for the treatment of,nasolabial folds, or wrinkles ... follow-up period of the study., Isolagen also ...
... CLINICAL TRIAL RESULTS PUBLISHED IN THE JOURNAL OF ... 14 BioForm Medical,Inc. (Nasdaq: BFRM ) ... randomized, blinded comparative study of nasolabial fold,treatments reporting ... more effective than Restylane(R), the leading dermal filler,on ...
Cached Medicine Technology:Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies 2RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial 2RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial 3RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial 4
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
(Date:1/22/2015)... 2015 State Forestry Institute of Mecklenburg-Vorpommern ... with support from GEOSYSTEMS, a dedicated Hexagon Geospatial and ... leverage Hexagon Geospatial’s ERDAS APOLLO for cataloging, ... as point clouds and documents. This effort will enable ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... Iridoids and Other ... ... (TNI) today set itself apart from the superfruits of the world yet again as modern ... plant that enhances the overall ability of the body to adapt to stress. Noni assists ...
... ... Kidney Diseases recommends capsaicin as an effective skin care regimen to help relieve itching associated ... be extremely hot. Now there,s a new skin spray made with the essence of hot ... ...
... ... be a simple matter of getting information about coverage that,s already available ... making concerted efforts to direct the uninsured to coverage, efforts by ordinary ... Charles Smith-Dewey, founder of one of the Web,s most respect health insurance ...
... ... opportunity for educational institutes to discuss their security requirements and compare their current Digital ... , ... (PRWEB) March 4, 2010 -- GlobalSign Inc ( www.globalsign.com ), one of the longest ...
... found that using high-resolution CT-scans to screen for lymphangioleiomyomatosis, or ... who come to the emergency room for the first time ... online ahead of print publication in the American Thoracic Society,s ... Pulmonary LAM is a rare but serious lung ...
... , ... help consumers keep track of their calories by scanning the barcodes on food items has gone ... ... who want to keep track of their daily nutritional intake by scanning the barcodes of items ...
Cached Medicine News:Health News:Tahitian Noni Bioactive Beverages™ Are Adaptogenic 2Health News:Hot Pepper Itch Remedy Targets Kidney Disease Patients Suffering From Chronic Pruritus 2Health News:Consumer Health Insurance Site Founder: Health Reform or No Health Reform, Americans Can Help Reduce Rolls of the Uninsured 2Health News:Consumer Health Insurance Site Founder: Health Reform or No Health Reform, Americans Can Help Reduce Rolls of the Uninsured 3Health News:Consumer Health Insurance Site Founder: Health Reform or No Health Reform, Americans Can Help Reduce Rolls of the Uninsured 4Health News:Consumer Health Insurance Site Founder: Health Reform or No Health Reform, Americans Can Help Reduce Rolls of the Uninsured 5Health News:GlobalSign to Demonstrate Online Security Solutions to Educational Institutes at NERCOMP Conference 2Health News:GlobalSign to Demonstrate Online Security Solutions to Educational Institutes at NERCOMP Conference 3Health News:GlobalSign to Demonstrate Online Security Solutions to Educational Institutes at NERCOMP Conference 4Health News:GlobalSign to Demonstrate Online Security Solutions to Educational Institutes at NERCOMP Conference 5Health News:CT-scan screening for LAM in women with collapsed lung is cost-effective 2Health News:CT-scan screening for LAM in women with collapsed lung is cost-effective 3Health News:Barcode Joins the Battle of the Bulge in New iPhone App 2
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent....
Alkaline phosphatase FS (IFCC). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of alkaline phosphatase activity in serum or plasma. Kinetic reaction. 405 nm wavelength. 830 U/L at 30C linearity. Single vial, dry powder reagent....
For the direct quantitative determination of low density lipoprotein cholesterol (LDL-C) in human serum or plasma. For in vitro diagnostic use only....
Medicine Products: